[新聞] 醣質定序

看板Bioindustry (生物科技)作者 (冰裂疊影)時間20年前 (2004/10/13 23:19), 編輯推噓0(000)
留言0則, 0人參與, 最新討論串1/1
學生時期覺得醣類研究相當複雜,未能建立什麼概念,今天看到這新聞還真覺得 美妙。這影響生技產業重要因素不僅在於醣類本身有醫療功效外,更能大幅改善 生技學名藥的醣基化的不確定性。 出處:http://biz.yahoo.com/prnews/041012/netu044_1.html 標題:Momenta Pharmaceuticals' Technology Featured in Nature Reviews 內容: 請參照網址內容 延伸閱讀: 1.About Momenta Momenta Pharmaceuticals, Inc. is a biotechnology company specializing in the sequencing and engineering of complex sugars for the development of improved versions of existing drugs, the development of novel drugs and the discovery of new biological processes. Momenta is also utilizing its ability to sequence sugars to create technology-enabled generic products. The Company's most advanced product candidate is M-Enoxaparin, a technology- enabled generic version of LovenoxR. Based on its understanding of complex sugars, Momenta has created a diversified pipeline of novel discovery and development candidates. Momenta was founded in 2001 and is headquartered in Cambridge, MA. 2.給生物科技加點「醣」 http://www.sciam.com.tw/circus/circusshow.asp?FDocNo=154&DocNo=245&CL=21 -- ※ 發信站: 批踢踢實業坊(ptt.cc) ◆ From: 210.244.69.64
文章代碼(AID): #11RKTjFA (Bioindustry)
文章代碼(AID): #11RKTjFA (Bioindustry)